Logo Logo
Hilfe
Hilfe
Switch Language to English

Andrassy, Joachim; Guba, Markus; Habicht, Antje; Fischereder, Michael; Pratschke, Johann; Pascher, Andreas; Heller, Katharina M.; Banas, Bernhard; Hakenberg, Oliver; Vogel, Thomas; Meiser, Bruno; Dick, Andrea; Werner, Jens und Kauke, Teresa (2020): Early conversion to a CNI-free immunosuppression with SRL after renal transplantation-Long-term follow-up of a multicenter trial.
In: PLOS One 15(8), e0234396 [PDF, 1MB]

Abstract

Introduction: Early conversion to a CNI-free immunosuppression with SRL was associated with an improved 1- and 3- yr renal function as compared with a CsA-based regimen in the SMART-Trial. Mixed results were reported on the occurrence of donor specific antibodies under mTOR-Is. Here, we present long-term results of the SMART-Trial. Methods and materials N = 71 from 6 centers (n = 38 SRL and n = 33 CsA) of the original SMART-Trial (ITT n = 140) were enrolled in this observational, non-interventional extension study to collect retrospectively and prospectively follow-up data for the interval since baseline. Primary objective was the development of dnDSA. Blood samples were collected on average 8.7 years after transplantation. Results Development of dnDSA was not different (SRL 5/38, 13.2% vs. CsA 9/33, 27.3%;P = 0.097). GFR remained improved under SRL with 64.37 ml/min/1.73m(2)vs. 53.19 ml/min/1.73m(2)(p = 0.044). Patient survival did not differ between groups at 10 years. There was a trend towards a reduced graft failure rate (11.6% SRL vs. 23.9% CsA, p = 0.064) and less tumors under SRL (2.6% SRL vs. 15.2% CsA, p = 0.09). Conclusions: An early conversion to SRL did not result in an increased incidence of dnDSA nor increased long-term risk for the recipient. Transplant function remains improved with benefits for the graft survival.

Dokument bearbeiten Dokument bearbeiten